Literature DB >> 22550126

Clinical outcome of catheter ablation in patients with nonparoxysmal atrial fibrillation: results of 3-year follow-up.

Tze-Fan Chao1, Hsuan-Ming Tsao, Yenn-Jiang Lin, Chin-Feng Tsai, Wei-Shiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Ta-Chuan Tuan, Kazuyoshi Suenari, Cheng-Hung Li, Beny Hartono, Hung-Yu Chang, Kibos Ambrose, Tsu-Juey Wu, Shih-Ann Chen.   

Abstract

BACKGROUND: Catheter ablation of atrial fibrillation (AF) became an effective therapy for patients with drug-refractory AF, and the indications have broadened to include nonparoxysmal AF patients. However, data about the long-term effectiveness of ablation in patients with nonparoxysmal AF are lacking. The aim of the present study was to investigate the long-term outcomes of catheter ablation in patients with nonparoxysmal AF. METHODS AND
RESULTS: A total of 88 nonparoxysmal AF patients who received a stepwise catheter ablation (isolation of the pulmonary veins plus substrate modification) from 2006 to 2008 were enrolled. Freedom of recurrence was defined as the absence of atrial arrhythmias without using any antiarrhythmic agents after the catheter ablation. There were 63 patients (71.6%) with recurrences (47 patients with AF and 16 patients with atrial flutter/atrial tachycardia) after the initial procedure during a median follow-up period of 36.8 months. A CHADS2 score of ≥3 and the left atrial (LA) diameter were significant predictors of recurrences in the multivariable analysis. Of the patients with CHADS2 scores of ≥3 and an LA dimension≥44 mm, all had recurrences within 1 year after the initial procedure. The overall recurrence-free rate could increase to 47.7% after the second procedure and 51.1% after the third procedure.
CONCLUSIONS: The long-term recurrence-free rate of ablation in nonparoxysmal AF was only 28.4% after a single procedure, and multiple procedures were necessary to raise the recurrence-free rate. The CHADS2 score and LA dimension may help us to identify patients who will have recurrences after catheter ablations of nonparoxysmal AF.

Entities:  

Mesh:

Year:  2012        PMID: 22550126     DOI: 10.1161/CIRCEP.111.968032

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  37 in total

1.  The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation.

Authors:  Jelena Kornej; Gerhard Hindricks; M Benjamin Shoemaker; Daniela Husser; Arash Arya; Philipp Sommer; Sascha Rolf; Pablo Saavedra; Arvindh Kanagasundram; S Patrick Whalen; Jay Montgomery; Christopher R Ellis; Dawood Darbar; Andreas Bollmann
Journal:  Clin Res Cardiol       Date:  2015-04-17       Impact factor: 5.460

2.  Reduction of radiation exposure during ablation of atrial fibrillation.

Authors:  Ralph Schneider; Jörg Lauschke; Cindy Schneider; Tina Tischer; Aenne Glass; Dietmar Bänsch
Journal:  Herz       Date:  2015-05-20       Impact factor: 1.443

Review 3.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

Review 4.  Immunopathogenesis and biomarkers of recurrent atrial fibrillation following ablation therapy in patients with preexisting atrial fibrillation.

Authors:  John H Rosenberg; John H Werner; Gilman D Plitt; Victoria V Noble; Jordan T Spring; Brooke A Stephens; Aleem Siddique; Helenmari L Merritt-Genore; Michael J Moulton; Devendra K Agrawal
Journal:  Expert Rev Cardiovasc Ther       Date:  2018-12-29

5.  Very long-term outcomes after a single catheter ablation procedure for the treatment of atrial fibrillation-the protective role of antiarrhythmic drug therapy.

Authors:  João Mesquita; Diogo Cavaco; António Miguel Ferreira; Francisco Moscoso Costa; Pedro Carmo; Francisco Morgado; Miguel Mendes; Pedro Adragão
Journal:  J Interv Card Electrophysiol       Date:  2018-03-06       Impact factor: 1.900

Review 6.  Translational research in atrial fibrillation: a quest for mechanistically based diagnosis and therapy.

Authors:  Felipe Atienza; Raphael P Martins; José Jalife
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-09-27

Review 7.  Towards a Mechanistic Understanding and Treatment of a Progressive Disease: Atrial Fibrillation.

Authors:  Felix Yang; Joseph Tiano; Suneet Mittal; Mintu Turakhia; Israel Jacobowitz; Yisachar Greenberg
Journal:  J Atr Fibrillation       Date:  2017-10-31

8.  Comparing Safety and Efficacy of Irrigated Radiofrequency Catheter Ablation Versus Combined Cryoballoon and Catheter Ablation for Persistent Atrial Fibrillation.

Authors:  Ioanna Kosmidou; Kyari Sumayin; Thomas Deering; Andrew Wickliffe; Sricharan Kanitpudi; Stephen Prater; Dan Dan
Journal:  J Atr Fibrillation       Date:  2013-10-31

9.  [Long-term results of catheter ablation of atrial fibrillation: cure or just palliation?].

Authors:  Kerstin Bode; Sascha Rolf; Philipp Sommer; Sergio Richter; Gerhard Hindricks
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2014-08-01

10.  Enlargement of the left atrium is associated with increased infiltration of immune cells in patients with atrial fibrillation who had undergone surgery.

Authors:  Takeshi Yamashita; Akiko Sekiguchi; Shinya Suzuki; Takayuki Ohtsuka; Koichi Sagara; Hiroaki Tanabe; Takashi Kunihara; Hitoshi Sawada; Tadanori Aizawa
Journal:  J Arrhythm       Date:  2014-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.